向明钧, 方先松, 马明星, 谭德勇. 应用比较蛋白组学技术筛选乳腺癌血清标志物[J]. 云南大学学报(自然科学版), 2011, 33(4): 479-483 .
引用本文: 向明钧, 方先松, 马明星, 谭德勇. 应用比较蛋白组学技术筛选乳腺癌血清标志物[J]. 云南大学学报(自然科学版), 2011, 33(4): 479-483 .
Searching the breast cancer serum marker by using the comparative proteomics technology[J]. Journal of Yunnan University: Natural Sciences Edition, 2011, 33(4): 479-483 .
Citation: Searching the breast cancer serum marker by using the comparative proteomics technology[J]. Journal of Yunnan University: Natural Sciences Edition, 2011, 33(4): 479-483 .

应用比较蛋白组学技术筛选乳腺癌血清标志物

Searching the breast cancer serum marker by using the comparative proteomics technology

  • 摘要: 为了寻找乳腺癌血清标志蛋白标志物,本研究用试剂盒去除血清样品中的高丰度蛋白,通过固相pH梯度双向凝胶电泳分离乳腺癌病人血清和非乳腺癌血清,银染显色,分析比较电泳图谱寻找差异蛋白.用基质辅助激光解吸电离飞行时间质谱测定差异蛋白的肽指纹图谱,MASCOT软件分析确定为何种蛋白,然后用蛋白印迹验证与乳腺癌发生关系密切的差异蛋白.本研究获得了分辨率高、重复性好的双向电泳银染图谱,得到3个差异明显的蛋白,经肽指纹分析并结合数据库查询,初步鉴定为人血凝级联反应中的关键酶、人体细胞凋亡蛋白抑制剂样蛋白ILP-2、人体HP蛋白.蛋白印迹研究表明ILP-2在乳腺癌血清中的含量明显高于非乳腺癌血清样本,该蛋白有可能是乳腺癌标志物.

     

    Abstract: Early diagnosis is a one of the key to improve the breast cancer patients' prognosis.To investigate the breast cancer serum-biomarkers,high-abundant protein was depleted from 400(portion) breast cancer patients' serum and 40 healthy control serum.The enriched proteins were then separated by 2D-PAGE (two-dimensional polyacrylamide gel electrophoresis) and the gels were dyed by silver-stain,then three different proteins were eluted from the gels.MOLDI TOF MS (matrix- assisted laser desorption ionization flying mass) analysis revealed the identity of those proteins are:① human crystal structure of the fxia catalytic domain in complex with Ecotinm84r;② human IAP-like protein 2 (Inhibitor of apoptosis protein (IAP)-like protein-2 (ILP-2), and ③ haptoglobin alpha (2FS)-beta precursor (HP).Western-blot revealed that ILP-2 has higher concentration in breast cancer patients serum compare to those control subjects and it is a hopeful serum-biomarker for diagnosis of breast cancer.This study provides a practicable approach to seek any other potential candidate as early diagnostic biomarkers in human malignant tumors

     

/

返回文章
返回